Statement of Changes in Beneficial Ownership (4)
August 04 2021 - 6:18PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Lerman Bradley E |
2. Issuer Name and Ticker or Trading Symbol
Medtronic plc
[
MDT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP General Counsel & Corp Sec |
|
(Last)
(First)
(Middle)
710 MEDTRONIC PKWY MS LC300 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/2/2021 |
|
(Street)
MINNEAPOLIS, MN 55432
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Ordinary Shares | 8/2/2021 | | S(1) | | 4000 | D | $131.52 | 48194 (2) | D | |
| Ordinary Shares | 8/2/2021 | | F | | 5450 | D | $131.31 | 42744 | D | |
| Ordinary Shares | 8/2/2021 | | A(3) | | 6019 | A | $0 | 48763 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | $131.26 | 8/2/2021 | | A | | 51423 | | 8/2/2022 (4) | 8/2/2031 | Ordinary Shares | 51423 | $0 | 51423 | D | |
| Stock Option (Right to Buy) | $131.26 | 8/2/2021 | | A | | 1085 | | 8/2/2022 (4) | 8/2/2031 | Ordinary Shares | 1085 | $0 | 1085 | D | |
| Performance Share Units | (5) | 8/2/2021 | | A | | 15047 (6) | | (7) | (7) | Performance Share Units | 15047 | $0 | 15047 | D | |
| Explanation of Responses: |
| (1) | This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
| (2) | This balance increased by 651 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. |
| (3) | The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. |
| (4) | These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. |
| (5) | Each performance share unit represents a contingent right to receive one share of Medtronic common stock. |
| (6) | The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,047 shares will be issued. The actual number of shares to be issued could range from a low of 3,010 at minimum performance to a high of 30,094 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. |
| (7) | Vests on August 2, 2024. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Lerman Bradley E
710 MEDTRONIC PKWY MS LC300
MINNEAPOLIS, MN 55432 |
|
| SVP General Counsel & Corp Sec |
|
Signatures
|
| /s/ Thomas L. Osteraas, attorney-in-fact | | 8/4/2021 |
| **Signature of Reporting Person | Date |
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024
